MARii MARii Institute welcomes industry players to leverage on its technologies in recovery process

KUALA LUMPUR, The Malaysia Automotive, Robotics and IoT Institute (MARii) is welcoming industry players to leverage on its technologies so as to expedite their recovery process amid the reopening of key economic sectors.

Chief executive officer Datuk Madani Sahari said MARii is committed to helping industry players digitalise their operations, enhance engineering capabilities and provide solutions through cloud-based operations.

“MARii offers numerous platforms to deploy data-driven management and operations within businesses, such as the recently announced MARii Enterprise Resource Planning (MARii ERP), high performance cloud computing, and many other digital platforms that can be customised to the needs of the industry.

“The key takeaway is that industry players can leverage on the various technologies developed by MARii to optimise their resources – ensuring that its manpower, infrastructure, and equipment work to add value to their production,” he said.

Since 2015, MARii has developed in-house Industry 4.0 technologies for deployment to local companies.

“These technologies range from a wide array of applications to digitalise the entire chain of activities within the industry. These include computer-aided design (CAD) leasing and training, additive manufacturing, autonomous robotics, computer simulations, virtual reality, enterprise resource planning (ERP), and many more,” he added.

Source: BERNAMA News Agency

BNM: Banks continue to set aside additional provisions against potential credit losses

KUALA LUMPUR, Banks continue to set aside additional provisions against potential credit losses, which currently stand at 1.9 per cent of total banking system loans.

Bank Negara Malaysia (BNM) in its monthly highlights – July 2021 report, said overall gross impaired loans ratio increased marginally to 1.7 per cent (June 2021: 1.6 per cent), driven by the household segment.

“Banks continue to facilitate repayment assistance for viable borrowers facing temporary financial difficulties amid credit risk outlook that remains challenging,” the central bank said.

Meanwhile, banking system liquidity position remained supportive of financial intermediation, it said.

The banking system continued to maintain healthy liquidity buffers with the liquidity coverage ratio (LCR) remaining strong in July (June 2021: 149.1 per cent).

“Banks’ funding profile remained stable amid sustained growth in deposits as individuals, businesses and non-bank financial institutions continue to maintain precautionary cash buffers,” BNM added.

Source: BERNAMA News Agency

smartTrade expands partnership with leading Japanese FX company SBI Liquidity Market

KUALA LUMPUR, smartTrade Technologies, a pioneer in multi-asset electronic trading solutions, has announced an expanded partnership with SBI Liquidity Market, a Japanese leading FX infrastructure solution and liquidity provider.

According to a statement, smartTrade will provide support for SBI FXTRADE’s cryptocurrency derivative trading operations, which complement the existing FX business of SBI Liquidity Market.

As part of the agreement, SBI has also moved its trading facility into smartTrade’s Tokyo data centre to ensure its infrastructure is constantly monitored and refreshed as their business grows as well as to take advantage of smartTrade’s fully managed services, including enhanced security and redundancy capabilities.

The expansion comes as both retail and institutional interest in cryptocurrency trading continues to soar in the Japanese market.

Co-founder and Chief Executive Officer of smartTrade Technologies, David Vincent, said: “This unprecedented and volatile year demonstrated the need for high performance trading infrastructure capable of withstanding all circumstances.”

“We’re pleased that what we’ve been able to offer leading companies such as SBI, such resilience. Today’s announcement is a vote of confidence that we will continue to work together with our customers to deliver them the infrastructure they need to succeed.”

Meanwhile, Executive Director, SBI Liquidity Market, Itsushi Morimoto said: “We are pleased to grow this relationship as we increasingly work to meet our clients growing requirements and desire to trade in a wide variety of digital currencies. smartTrade has been the best kind of partner – one that adapts with the business, supporting our change and growth.”

SBI has been a smartTrade client since 2013, when the company chose LiquidityFX as its connectivity, aggregation and smart order routing partner to achieve best execution.

smartTrade provides agile end-to-end trading solutions supporting Foreign Exchange, Fixed Income, Equities, Derivatives (including Options), Cryptocurrencies and Money Markets.

Source: BERNAMA News Agency

MATRADE’s eBizMatch generates RM910.56 mln sales for January-July

BANGKOK, The COVID-19 pandemic, border closures and lockdowns never stop Malaysia External Trade Development Corp (MATRADE) efforts in introducing Malaysian companies to new potential markets and clients.

By adopting digitalisation in trade promotion, MATRADE had organised a total of 1,086 eBizMatch between 674 Malaysian exporters and 517 foreign buyers in the first seven months of 2021.

MATRADE chief executive officer Mohd Mustafa Abdul Aziz said eBizMatch between Malaysian exporters and foreign buyers generated RM910.56 million sales from January to July this year.

“In ASEAN, MATRADE had conducted 278 eBizMatch connecting 99 buyers with 168 Malaysian exporters,” he said at the inaugural Indochina Malaysian Business Chambers e-Summit 2021 today.

He added that last year MATRADE conducted a total of 1,365 online business matching or eBizMatch for 1,115 Malaysian companies and 703 foreign buyers worldwide with 173 meetings for ASEAN buyers.

“Total sales recorded for 2020 eBizMatch was RM1.08 billion,” he said.

Mohd Mustafa said MATRADE’s digitalisation efforts in promoting exports continue through its participation in the ASEAN Online Sales Day (AOSD).

“This is part of our continuous commitment to assist Malaysian SMEs in sustaining their operations and businesses during these challenging times. This online platform assists exporters to expand its exports into all ASEAN countries through established ecommerce channels (onlineasean.com), offering an array of products with special deals,” he said.

Meanwhile, Mohd Mustafa said ASEAN remained as an important and strategic trading partner for Malaysia, accounting for 25.2 per cent of Malaysia’s total trade in 2020.

He said Malaysia’s total trade with the five Indochina countries was valued at RM134.6 billion or 30 per cent of total trade with ASEAN, last year.

“Due to the market uncertainties, Malaysia’s total trade with Indochina countries decreased by 18.4 per cent in 2020 compared to 2019,” he said.

As merchandise trade expanded more rapidly than expected, Mohd Mustafa said Malaysia’s total trade surpassed RM1 trillion in just six months this year, the shortest period to breach this milestone.

In the first seven months this year, he said trade with ASEAN rose by 25.8 per cent to RM315.22 billion compared to the same period last year.

“Exports to this region edged up by 23.2 per cent to RM189.58 billion, while imports from ASEAN expanded by 29.8 per cent to RM125.64 billion. Trade surplus surged by 12.1 per cent to RM63.94 billion,” he said.

He added that trade between Malaysia and Indochina recorded a double-digit growth of 28.8 per cent compared to the same period last year.

The Indochina Malaysian Business Chambers e-Summit 2021, a virtual summit, gathered all five Malaysian ambassadors to the Indochina countries – Cambodia, Laos, Myanmar, Thailand and Vietnam and members of the business communities.

The inaugural e-Summit was mooted by Malaysia’s ambassador to Cambodia Eldeen Husaini Mohd Hashim.

“The virtual summit is a paradigm shift to promote borderless trade amid the ongoing COVID-19 pandemic in the Indochina region.

“As the pandemic swaps us with chaos and uncertainty, I believe the embassies and Malaysian business chambers as well as key players will ensure continuation of businesses and thrive through COVID-19,” he told Bernama.

Source: BERNAMA News Agency

Distribution of Etesevimab/JS016 in the US Reopened

SHANGHAI, China, Aug. 29, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the United States Food and Drug Administration (the “FDA”), alongside the Office of the Assistant Secretary for Preparedness and Response, has resumed the shipment and distribution of etesevimab and bamlanivimab administered together (the “Therapy”), according to the company’s global partner Eli Lilly and Company (NYSE: LLY). Direct ordering will be available to authorized states in the U.S. effective immediately.

The decision to resume distribution aligns with the FDA’s issuance of an updated fact sheet (the “Fact Sheet”) and a revised letter of authorization for etesevimab and bamlanivimab together. These include a revised limitation of authorized use, only allowing use in the states, territories, and U.S. jurisdictions with a low prevalence of variants that are resistant to treatment with the antibodies.

The Delta variant (the “Delta”) currently accounts for nearly 96 percent of all identified COVID-19 cases in the U.S. As shown in revisions to the Fact Sheet, pseudovirus and authentic virus studies demonstrate that etesevimab and bamlanivimab together retained neutralization activity against the Alpha variant and the Delta.

Over the last several months, prevalence of variants varies by state, region and even country and can change rapidly. As variants continue to evolve and their patterns of transmission and prevalence shift, Eli Lilly and Company (“Lilly”), a partner of the Company, will continue to work with governments and regulators worldwide to ensure the Therapy is available to appropriate patients.

About Etesevimab (JS016/LY-CoV016)
Etesevimab is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from the Company after it was jointly developed by the Company and the Institute of Microbiology of Chinese Academy of Science. The Company leads development in Greater China (including mainland China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region and the Taiwan region), while Lilly leads development in the rest of the world.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology of the Chinese Academy of Sciences and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+86 021-6105 8800

Lajim Ukin contributed significantly in shaping Bersatu direction – Muhyiddin

KUALA LUMPUR, The late Datuk Seri Lajim Ukin was an experienced politician who contributed significantly in shaping the direction of Parti Pribumi Bersatu Malaysia (Bersatu), said party president, Tan Sri Muhyiddin Yassin.

Muhyiddin, in conveying his condolences to the family of Lajim, who died early today, said that the passing of Lajim, 66, who was also a member of the Bersatu Supreme Council, was a great loss for him.

“Lajim was a friend, whom I have known for a long time and we served together in the government before. Representing the party and the Perikatan Nasional, I express my deepest appreciation and thanks for his services.

“Let us recite Al-Fatihah (for the deceased). May his good deeds be rewarded by Allah and his soul be placed among the pious,” said the former Prime Minister in a post on his Facebook today.

Lajim, Amanah Ikhtiar Malaysia (AIM) executive chairman, who was also a former deputy chief minister of Sabah, died of COVID-19 at KPJ Hospital, Kota Kinabalu, Sabah at 6.23 this morning, according to his wife, Datin Seri Normilah Sion.

A former Beaufort Member of Parliament and Klias assemblyman, Lajim had also served as federal deputy minister in the transport, and housing and local government portfolios.

Meanwhile, the sixth Prime Minister Datuk Seri Najib Tun Razak, through his social media account, also conveyed his condolences to Lajim’s family members and prayed that Allah would forgive his sins and place him among the faithful.

Source: BERNAMA News Agency

Heed Sultan Nazrin’s decree in fight against COVID – Perak PAS

BAGAN SERAI, The Sultan of Perak Sultan Nazrin Shah’s decree during the opening of the Perak State Assembly, in which he called for high-level political maturity and to avoid clashing with one another during the COVID-19 pandemic, should be heeded by all parties, including the opposition.

Perak PAS secretary Mohd Akmal Kamarudin said that in facing the pandemic, all parties should work together to curb the spread of the virus and not make allegations that could trigger misunderstandings.

“Any good proposals for the government are very welcomed in the interest of the people of Perak, especially in efforts to combat COVID-19,” Mohd Akmal, who is also the state Health, Science, Environment and Green Technology Committee chairman, told Bernama.

During the state assembly sitting at Bangunan Perak Darul Ridzuan here on Thursday (Aug 26), Sultan Nazrin said the government should pave the way towards minimising political disputes for the benefit of the state and the people.

Source: BERNAMA News Agency